FDA hands Gilead a stun­ning re­jec­tion for block­buster RA can­di­date fil­go­tinib, deal­ing CEO O’Day a ma­jor set­back

In a sur­prise twist, the FDA has re­ject­ed Gilead’s mar­ket­ing ap­pli­ca­tion for fil­go­tinib, deal­ing a body blow to Daniel O’Day’s hopes for a rapid im­prove­ment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER